GT Biopharma (GTBP) Stock Price
GT Biopharma Price
Revenue at GT Biopharma has contracted by 38.6% per year over the past 11 years to 27,000.00 USD. GT Biopharma's net margin stands at -533,970.4%, down from -1,512.0% several years earlier. Analysts set a median price target of 8.16 USD, implying 19.6% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
GT Biopharma stock price
GT Biopharma business model & stock analysis
Frequently asked questions about GT Biopharma
Analysts currently set an average price target of 8.16 USD for the GT Biopharma stock (median: 8.16 USD), implying +19.6 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the GT Biopharma stock: 6 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the GT Biopharma share trades at 6.09 EUR (6.82 USD).
The GT Biopharma share (GTBP) is listed on 6 stock exchanges, including: NASDAQ (GTBP), Frankfurt (OXI.F), München (OXI.MU), Düsseldorf (OXI.DU), Paris (GTBP.PA).
The revenue cannot currently be calculated for GT Biopharma.
The expected profit of GT Biopharma is -20.40 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of GT Biopharma is currently -0.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the GT Biopharma stock.
The P/S cannot be calculated for GT Biopharma currently.
The Eulerpool Quality Score for GT Biopharma is 2/10.
The ISIN of GT Biopharma is US36254L3087. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of GT Biopharma is A2QQPL. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of GT Biopharma is GTBP. The ticker symbol is used to trade GT Biopharma shares on the stock exchange.
GT Biopharma stock
GT Biopharma Peer Group
GT Biopharma Ticker
All fundamentals and in-depth analysis of GT Biopharma
Our stock analysis for GT Biopharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GT Biopharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.